(Q38051192)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

P2Y12 receptor: platelet thrombus formation and medical interventions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Denise E Jackson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

1 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Hematology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

572-587

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054651%20AND%20SRC:MED&resulttype=core&format=json

The platelet P2 receptors as molecular targets for old and new antiplatelet drugs

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Platelet-collagen interaction: is GPVI the central receptor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Central role of the P2Y12 receptor in platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Nucleotide receptor signaling in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Pharmacological profiles of cloned mammalian P2Y-receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Characterization of the UDP-glucose receptor (re-named here the P2Y14 receptor) adds diversity to the P2Y receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Advances in signalling by extracellular nucleotides. the role and transduction mechanisms of P2Y receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Knock-out mice reveal tissue-specific roles of P2Y receptor subtypes in different epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Quantification of ADP and ATP receptor expression in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Role of P2Y1 purinoceptor in ADP‐induced platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Identification of the platelet ADP receptor targeted by antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Adenine triphosphate nucleotides are antagonists at the P2Y receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Purification and Functional Reconstitution of the Human P2Y12Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

N-linked glycosylation of platelet P2Y12 ADP receptor is essential for signal transduction but not for ligand binding or cell surface expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

G proteins: transducers of receptor-generated signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

ADP and platelets: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Activation of Rap1B by G(i) family members in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Galpha12 and galpha13 are phosphorylated during platelet activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Defective platelet activation in G alpha(q)-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Impaired activation of murine platelets lacking G alpha(i2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Taming platelets with cyclic nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Resistance to clopidogrel: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Phosphorylation of focal adhesion vasodilator-stimulated phosphoprotein at Ser157 in intact human platelets correlates with fibrinogen receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Monitoring of clopidogrel action: comparison of methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The P2Y(12) receptor induces platelet aggregation through weak activation of the alpha(IIb)beta(3) integrin--a phosphoinositide 3-kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

PI 3-kinase p110beta: a new target for antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Signaling by distinct classes of phosphoinositide 3-kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Identification of P2Y12-dependent and -independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Rap1 signalling: adhering to new models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Akt Activation in Platelets Depends on Gi Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Role of G protein-gated inwardly rectifying potassium channels in P2Y12 receptor-mediated platelet functional responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Src tyrosine kinase is a novel direct effector of G proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Thrombin and thrombin receptor agonist peptide induce tyrosine phosphorylation and tyrosine kinases in the platelet cytoskeleton. Translocation of pp60c-src and integrin alpha IIb beta 3 (glycoprotein IIb/IIIa) is not required for aggregation, but i

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Differential requirements for calcium and Src family kinases in platelet GPIIb/IIIa activation and thromboxane generation downstream of different G-protein pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Reciprocal cross-talk between P2Y1 and P2Y12 receptors at the level of calcium signaling in human platelets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A mitogen-activated protein kinase-dependent signaling pathway in the activation of platelet integrin alpha IIbbeta3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

p42 mitogen-activated protein kinase and p90 ribosomal S6 kinase are selectively phosphorylated and activated during thrombin-induced platelet activation and aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Regulation and functional consequences of ADP receptor-mediated ERK2 activation in platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Distinct regulation of cytosolic phospholipase A2 phosphorylation, translocation, proteolysis and activation by tumour necrosis factor-receptor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Molecular defects of the platelet P2 receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

ADP receptors and clinical bleeding disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Haploinsufficiency of the platelet P2Y12 gene in a family with congenital bleeding diathesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are h

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Usefulness of a flow cytometric analysis of intraplatelet vasodilator-stimulated phosphoprotein phosphorylation for the detection of patients with genetic defects of the platelet P2Y(12) receptor for ADP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

21 January 2018

New P2Y(12) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

ADP receptor antagonism: what's in the pipeline?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The safety and efficacy of clopidogrel versus ticlopidine in Japanese stroke patients: combined results of two Phase III, multicenter, randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Clopidogrel: a review of its mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Clopidogrel resistance: a new chapter in a fast-moving story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

21 January 2018

Clopidogrel resistance?

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The disposition of prasugrel, a novel thienopyridine, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Dyspnoea after antiplatelet agents: the AZD6140 controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The P2Y12 receptor as a therapeutic target in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Intravenous platelet blockade with cangrelor during PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Platelet inhibition with cangrelor in patients undergoing PCI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Elinogrel: pharmacological principles, preclinical and early phase clinical testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percuta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Thienopyridines, but not elinogrel, result in off-target effects at the vessel wall that contribute to bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

A Clopidogrel-Insensitive Inducible Pool of P2Y12 Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y12 Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Vasodilator-stimulated protein phosphorylation in platelets is mediated by cAMP- and cGMP-dependent protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-012-1188-5

Ticagrelor: An investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome

21 January 2018

1 reference

12 December 2020

Ultrastructural studies of platelet aggregates from human subjects receiving clopidogrel and from a patient with an inherited defect of an ADP-dependent pathway of platelet activation

1 reference

12 December 2020

P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP

1 reference

12 December 2020

Receptors for purines and pyrimidines

1 reference

12 December 2020

Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect

1 reference

12 December 2020

A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation

1 reference

12 December 2020

Resistance to thromboembolism in PI3Kgamma-deficient mice.

1 reference

12 December 2020

A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase

1 reference

12 December 2020

Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study

1 reference

12 December 2020

Translocation of pp60c-src to the cytoskeleton during platelet aggregation

1 reference

12 December 2020

Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells

1 reference

12 December 2020

Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization

1 reference

12 December 2020

Cost-effectiveness of clopidogrel treatment in percutaneous coronary intervention: a European model based on a meta-analysis of the PCI-CURE, CREDO and PCI-CLARITY trials

1 reference

12 December 2020

From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis

1 reference

12 December 2020

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects

1 reference

12 December 2020

Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological comparison with another ADP receptor, the P2Y(1) receptor

1 reference

12 December 2020

Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months

1 reference

12 December 2020

cAMP is an important messenger for ADP-induced platelet aggregation

1 reference

12 December 2020

Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions

1 reference

12 December 2020

International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits

1 reference

12 December 2020

Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear

1 reference

12 December 2020

Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2

1 reference

12 December 2020

Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate

1 reference

12 December 2020

The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.

1 reference

12 December 2020

The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel

1 reference

12 December 2020

Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function

1 reference

12 December 2020

Identification of Gz alpha as a pertussis toxin-insensitive G protein in human platelets and megakaryocytes

1 reference

12 December 2020

Dual regulation of platelet protein kinase B

1 reference

12 December 2020

The human platelet ADP receptor activates Gi2 proteins

1 reference

12 December 2020

Identification of the P2Y(12) receptor: a novel member of the P2Y family of receptors activated by extracellular nucleotides

1 reference

12 December 2020

Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial

1 reference

12 December 2020